Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (DE:8E8)
FRANKFURT:8E8
8E8 Stock Chart & Stats
€0.47
€0.03(20.86%)
At close: 4:00 PM EST
€0.47
€0.03(20.86%)
Day’s Range― - ―
52-Week Range€0.18 - €0.69
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€30.93M
Enterprise Value€290.63M
Total Cash (Recent Filing)€24.85M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding48,535,545
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)10.19
Price to Sales (P/S)0.00
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet: Zero DebtZero debt materially lowers solvency and interest-cost risk for an R&D-stage biotech, preserving flexibility to fund programs via equity or partnerships rather than servicing loans. This structural conservatism reduces short- to medium-term bankruptcy risk and supports long-term investment optionality.
Focused Immuno‑oncology R&D PlatformA clear strategic focus on CAR T and oncolytic virus modalities targets high unmet oncology needs and aligns with durable secular demand for next‑gen immunotherapies. Specialization increases potential for meaningful clinical/partnering outcomes and long-term value capture if trials progress.
High Gross Profit When Revenue ExistsHistorical near‑full pass‑through gross margins indicate revenue, when realized, can be highly scalable and not heavily consumed by COGS. That structural margin profile supports attractive operating leverage potential as development programs commercialize or are licensed.
Bears Say
Persistent Operating And Net LossesOngoing operating and net losses erode equity and signal the company lacks self-sustaining profitability. Over a multi-month horizon this necessitates external financing or dilution, constrains reinvestment, and increases execution risk if clinical or commercial milestones slip.
Weak Cash Generation And Continued Cash BurnConsistent negative operating and free cash flow create dependency on equity raises or partnerships for runway. This structural cash shortfall limits strategic flexibility, risks dilution at unfavorable terms, and pressures program timelines if additional financing is delayed.
Revenue Volatility And Zero Revenue In 2025Large swings and a drop to zero revenue undermine predictable funding from operations and complicate partner negotiations and forecasting. Structural revenue unreliability increases reliance on milestones/grants and magnifies execution risk for sustained program development.
8E8 FAQ
What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.69 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is €30.93M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
Elicera Therapeutics AB’s upcoming earnings report date is Apr 28, 2026 which is in 52 days.
How were Elicera Therapeutics AB’s earnings last quarter?
Elicera Therapeutics AB released its earnings results on Feb 13, 2026. The company reported -€0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.013.
Is Elicera Therapeutics AB overvalued?
According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 48,535,545 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Elicera Therapeutics AB reported an EPS of -€0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.636%.
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in DE:8E8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Technical Analysis
Isofol Medical AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―